albaconazole

UR-9825 is the (1R,2R)-isomer; structure in first source

Also Known As:

7-chloro-3-(2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)quinazolin-4(3H)-one; UR 9825; UR-9825; 4(3H)-Quinazolinone, 7-chloro-3-((1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)-

Networked: 16 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - albaconazole: 16
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - albaconazole: 16

Experts

1.	van Rossem, Koen: 3 articles (01/2014 - 01/2013)
2.	Bonetti, Aline F: 1 article (02/2022)
3.	Domingos, Eric L: 1 article (02/2022)
4.	Fávero, Maria L D: 1 article (02/2022)
5.	Pontarolo, Roberto: 1 article (02/2022)
6.	Tonin, Fernanda S: 1 article (02/2022)
7.	Hedayati, Mohammad T: 1 article (01/2017)
8.	Ilkit, Macit: 1 article (01/2017)
9.	Rafati, Haleh: 1 article (01/2017)
10.	Seyedmousavi, Seyedmojtaba: 1 article (01/2017)

Related Diseases

1.	Infections 10/01/2009 - "The efficacy of albaconazole (ABC) was evaluated using a murine model of vaginal Candida albicans infection. " 06/01/2003 - "Doses of 15, 25, and 50 mg/kg of body weight/day for the new triazole albaconazole (ABC) were evaluated in an immunocompetent rabbit model of systemic infection with this mold. " 07/01/2001 - "In order to develop new approaches to the treatment of the severe and usually fatal infections caused by Scedosporium spp., the in vitro antifungal activities of four novel triazoles (posaconazole, ravuconazole, voriconazole, and UR-9825) and some current antifungals (amphotericin B, ketoconazole, itraconazole, and nystatin) were determined. "
2.	Vaginitis 10/01/2009 - "Efficacy of albaconazole against Candida albicans in a vaginitis model."
3.	scedosporiosis 06/01/2003 - "Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits."
4.	Mycoses (Diseases, Fungus) 02/01/2010 - "Most clinical trials with albaconazole have targeted mucocutaneous fungal infections. " 01/01/2013 - "Albaconazole is a novel triazole being developed for the oral treatment of fungal diseases. " 01/01/2014 - "Albaconazole is a triazole antifungal agent discovered at Palau Pharma SA (Barcelona, Spain) and currently being developed for the treatment of fungal infections of the nails. " 10/01/2009 - "A new generation of triazole agents (voriconazole, posaconazole, isavuconazole, ravuconazole and albaconazole) and the recent class of the echinocandins (caspofungin, micafungin and anidulafungin) have become available, and represent an alternative to conventional antifungals for serious fungal infection management. "
5.	Onychomycosis (Tinea Unguium) 09/01/2013 - "A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis." 09/01/2013 - "Albaconazole was well tolerated at all doses and resulted in high cure rates for onychomycosis." 01/01/2013 - "Once-weekly oral dosing with 400 mg albaconazole for 24 or 36 weeks resulted in high rates of clinical and mycological resolution for distal subungual onychomycosis, as well as a favorable safety and tolerability profile. " 09/01/2013 - "Evaluate efficacy and safety of albaconazole, a novel triazole, for once-weekly treatment of distal subungual onychomycosis of the great toenail. " 02/01/2022 - "Albaconazole 400 mg, posaconazole 200-400 mg, and terbinafine 250-350 mg were the most effective therapies for onychomycosis, while itraconazole 400 mg was the safest. "

Related Drugs and Biologics

1.	ER 30346 (ravuconazole)
2.	isavuconazole
3.	Triazoles
4.	posaconazole
5.	Voriconazole (Vfend)
6.	Itraconazole (Sporanox)
7.	Fluconazole (Zonal)
8.	Amphotericin B (Amphotericin)
9.	Echinocandins
10.	Nystatin (Mycostatin)

Related Therapies and Procedures

1.	Therapeutics